Press Esc to close

Welcome to Money Morning - Only the News You Can Profit From.

Close

This Says Our Favorite Biotech Is Off to the Races

Shares of a promising biotech we recommended back in February 2013 – jumped as much as 27% to a three-month high of $14.20 yesterday after the company said a new cancer drug met its main goal in a midstage clinical trial.

Its shares backtracked a bit as the day progressed but still closed 17.6% higher for the session. These shares have advanced 361% since we first told you about them. The stock has generated a peak gain of 456%, making it one of the 31 recommendations we’ve made to you that have doubled or better since we launched Private Briefing in August 2011. (More on that later…)

  • Featured Story

    Profit from the Huge Price Surge… That You've Created

    It's been five months since we last checked in on palladium, the precious metal so critical to the consumer electronics we use hundreds of times a day.
    At the time I said I was bullish for a number of market reasons.
    As it turns out, there were even more...
    Now it's time for another close look, since the bullish forces are only picking up speed.
    What's more, some new ones have materialized, pointing to a massively profitable palladium spike...Full Story
    Read More...
  • palladium prices